This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
SurModics (SRDX) Posts Earnings in Q4, Revenues Top Estimates
by Zacks Equity Research
SurModics' (SRDX) stellar fourth-quarter results benefit from higher product sales, royalties, research, development and other revenues.
Haemonetics (HAE) Q2 Earnings Beat Estimates, EPS View Up
by Zacks Equity Research
Continued momentum in new business generation and geographical expansions help Haemonetics (HAE) deliver strong results in Q2.
VWR Q3 Earnings Top, Sell-Off to Avantor Approaching Closure
by Zacks Equity Research
VWR's third-quarter report impresses with growth in Americas and EMEA-APAC segments. The transaction with Avantor is also in process.
Penumbra (PEN) Posts Earnings, Revenues Top Estimates in Q3
by Zacks Equity Research
Penumbra (PEN) witnesses strong growth across all geographical regions and product lines in Q3.
DaVita (DVA) Q3 Earnings Miss & Revenues Beat, '17 View Dull
by Zacks Equity Research
Strong growth in patient services is likely to boost DaVita's (DVA) growth trajectory in the coming quarters. DaVita's (DVA) continuous improvement in Kidney care is commendable as well.
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology (ALGN) consistently invests in R&D for product innovation.
Inogen (INGN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) stellar third-quarter numbers benefit from direct-to-consumer sales and lower cost of goods sold per unit.
Phibro Animal (PAHC) Beats on Q1 Earnings, Reiterates View
by Zacks Equity Research
Phibro Animal (PAHC) witnesses year-over-year improvement across all segments in Q1.
Wright Medical (WMGI) Portfolio Solid, Lower Extremities Dull
by Zacks Equity Research
Wright Medical (WMGI) is focusing on product innovation through research and development. However, lackluster international performance of the Lower extremities segment is a matter of concern.